Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Drug Delivery
Filter     Order     Display # 
Date Item Title
13 Jun 2007 Penwest Begins Dosing Phase IIa Clinical Study of Nalbuphine ER
13 Jun 2007 CombinatoRx and Angiotech Extend Research and Development Collaboration to Create Next Generation Drug Device and Local Delivery Medicines
12 Jun 2007 Kurve Technology and Schering-Plough Sign Expanded Technology Agreement
08 Jun 2007 Alkermes Announces Initiation of Phase I Clinical Study of AIR(R) Parathyroid Hormone
06 Jun 2007 Unigene Reports That Oral Calcitonin Phase III Clinical Study for Osteoarthritis Treatment is Initiated
03 Jun 2007 ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
02 Jun 2007 Arrowhead subsidiary, Insert, publishes interim Phase I data from human clinical trials for new cancer drug
01 Jun 2007 Indevus Announces Authorization for Approval of VANTAS(R) in Selected European Countries
01 Jun 2007 Skyepharma PLC - Twice daily ZYFLO CR(TM) (zileuton) extended-release tablets approved by the FDA for asthma
31 May 2007 Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors
30 May 2007 Positive Final Data from HyCAMPTM Phase II Trial in Metastatic Colorectal Cancer
29 May 2007 FUJIFILM, Cangen Biotechnologies Joint Development Agreement on Anti-cancer Drug Delivery System
26 May 2007 Iomai Announces Interim Results From Phase 1 Study of Its Patch-Based Vaccine for Seasonal Influenza
25 May 2007 Inovio Biomedical’s DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
25 May 2007 Emisphere Announces Initiation of Phase III Clinical Program of Oral Calcitonin for the Treatment of Osteoarthritis
23 May 2007 Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
23 May 2007 Phase 1b insulin clinical trial commenced
22 May 2007 Nektar Therapeutics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference
15 May 2007 GSK Returns Development Rights for MED2002
15 May 2007 BDSI Announces Positive Key Secondary Efficacy Endpoint Results for Bema Fentanyl
15 May 2007 Skyepharma PLC and Sciele Pharma Announce Successful Completion of New Sular(R) Formulation Clinical Trial Programme
11 May 2007 FDA Approves Schwarz Pharma's Neupro (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease in USA
09 May 2007 Oramed Pharmaceuticals Begins Phase 1 Human Clinical Trials
08 May 2007 Bema(TM) Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study
04 May 2007 Indevus Announces FDA Approval of SUPPRELIN(R)-LA
04 May 2007 Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose
03 May 2007 YM Biosciences Reports Aerolef(TM) Randomized Phase Iib Trial Meets Primary Endpoint In Patients With Post-Surgical Pain
03 May 2007 Expression Genetics, Inc. Receives Orphan Drug Grant from FDA for Clinical Development of EGEN-001 for Treatment of Ovarian Cancer
02 May 2007 Transport Pharmaceuticals Initiates Patient Enrollment In Phase 2 Study Of Solovir System For Herpes Labialis
02 May 2007 Cardium Advancing Excellarate to Phase 2b Clinical Study
02 May 2007 Phosphagenics to commence insulin clinical trial in May
01 May 2007 Apollo develops needle-free topical vaccine
01 May 2007 InSite Vision Announces FDA Approval for AzaSite(TM) Approval Triggers $19 Million Milestone Payment
27 Apr 2007 Alchemia reports preliminary positive efficacy data from HyCAMP Phase II trial
26 Apr 2007 BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
26 Apr 2007 ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
26 Apr 2007 Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
26 Apr 2007 MediGene Completes Patient Recruitment for Clinical Phase II Trial of EndoTAG(R)-1
25 Apr 2007 OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis
25 Apr 2007 Neuromed Licenses Phase 3 Chronic Pain Product from ALZA Corporation
24 Apr 2007 Alimera Sciences' Medidur(TM) Trial Exceeds 500 Patient Mark In Phase 3 Trial Enrollment
24 Apr 2007 Vectura Announces Successful Outcome of Second Phase IIb Clinical Study on Inhaled Erectile Dysfunction Product
21 Apr 2007 Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
21 Apr 2007 FDA Grants Full Approval for DepoCyt(R) for the Treatment of Lymphomatous Meningitis
20 Apr 2007 Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
17 Apr 2007 Metabasis Therapeutics Presents Results of a Clinical Study for Its Novel Liver-Targeted Product Candidate for the Treatment of HCC at American Association for Cancer Research
17 Apr 2007 Regulatory Review Allows LCT Diabetes Clinical Program to Proceed
17 Apr 2007 Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
13 Apr 2007 Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
05 Apr 2007 Innocoll Receives FDA Approval to Commence Phase 2 Clinical Development with its CollaRx(R) BUPIVACAINE IMPLANT for the Management of Post-operative Pain
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 Next > End >>
Results 101 - 150 of 411

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics